The Future of Specialty Spend: Navigating Biologics vs. Biosimilars

The landscape of pharmacy benefits is currently being reshaped by a new generation of medicine. For years, specialty spend has been dominated by biologics—complex, high-cost medications derived from living organisms. While these drugs have revolutionized the treatment of chronic conditions, they have also become the primary driver of unsustainable health plan costs.

The solution lies in the emergence of biosimilars. For brokers and plan sponsors, understanding the interplay between these two categories is the key to managing the future of specialty spend and achieving meaningful cost containment.

Understanding the Science: Biologics vs. Biosimilars

Unlike simple chemical pills, biologics are grown in living cells, making them impossible to replicate exactly.

• Biologics: These are the “innovator” drugs. Because they are the first of their kind, they enjoy patent protection that allows manufacturers to set high prices without competition.
• Biosimilars: A biosimilar is “highly similar” to an approved reference biologic. It has no clinically meaningful differences in terms of safety or potency.
• Interchangeability: Some biosimilars receive a specific FDA “interchangeable” designation, allowing pharmacists to substitute the biosimilar for the reference biologic without a new prescription.

The “Rebate Trap” and Fiduciary Risk

For plan sponsors, the biggest hurdle to biosimilar adoption isn’t clinical—it’s financial. Traditional PBMs often engage in “rebate walling,” where they keep high-cost biologics on the formulary because they provide massive rebates that the PBM may partially retain.

• The Net Cost Illusion: A PBM might show a high-cost biologic with a $4,000 rebate, while a biosimilar has no rebate but a $6,000 lower list price. In a broken system, the PBM may push the higher-cost drug to keep its portion of the rebate, even though the biosimilar is cheaper for the employer.
• ERISA and the CAA: Under the Consolidated Appropriations Act (CAA), employers are now held to a strict fiduciary standard regarding their health plan spend. Plan sponsors must be able to prove they are not overpaying for medications. If a cheaper, clinically equivalent biosimilar is available but ignored, it creates a significant compliance and legal liability for the company.

Putting Employee Health at the Forefront

While cost containment is vital for plan sustainability, the ultimate goal of any health benefit is the well-being of the employee. High-cost specialty medications are only effective if members can actually afford to take them.

• Lowering Out-of-Pocket Barriers: When a plan successfully transitions to biosimilars, the lower net cost can be passed down to the employee. This reduces the financial toxicity that often leads to “cost-related non-adherence,” where members skip doses or split pills because of high co-insurance.
• Ensuring Clinical Continuity: Biosimilars undergo rigorous FDA testing to ensure they provide the same therapeutic effect as the original biologic. Employees can transition to these lower-cost options with the confidence that their health outcomes will not be compromised.
• Sustainable Access: By managing specialty spend today, employers ensure they have the financial resources to continue offering high-quality coverage tomorrow. This long-term stability provides employees with the peace of mind that their lifesaving benefits will remain intact.

How SHARx Navigates the Specialty Landscape

Managing the transition to biosimilars requires an advocacy-based approach that puts the plan sponsor’s fiduciary health—and the employees’ health—first. SHARx helps brokers and employers capture the value of the biosimilar revolution through:

• Fiduciary Alignment: We do not profit from manufacturer rebates on high-cost biologics. Our goal is to find the lowest net cost, ensuring every cent of expense optimization stays with the client.
• Strategic Sourcing: By unbundling specialty claims from the traditional PBM cycle, we can pivot quickly to new biosimilar entries, ensuring plan sponsors aren’t trapped in high-cost legacy contracts.
• Compassionate Advocacy: We provide oversight and personal support needed to help members transition to biosimilar therapies seamlessly. We act as a bridge between the doctor, the pharmacy, and the member to ensure no one is left behind in the shift to a more sustainable model.

The Path Forward

The future of pharmacy benefits hinges on biosimilar adoption. While biologics offer lifesaving breakthroughs, the clinical equivalence of biosimilars provides the competition necessary to break the cycle of runaway specialty spend.